These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4035651)

  • 21. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.
    Khavkina LS; Rozenfeld MA; Leonova VB
    Thromb Res; 1995 Apr; 78(2):173-87. PubMed ID: 7482434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between gender difference in intravascular aggregation of platelets and the fibrinolytic pathway in the rat.
    Oyekan AO; Botting JH
    Arch Int Pharmacodyn Ther; 1991; 313():176-92. PubMed ID: 1816761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin.
    Camiolo SM; Thorsen S; Astrup T
    Proc Soc Exp Biol Med; 1971 Oct; 138(1):277-80. PubMed ID: 5125527
    [No Abstract]   [Full Text] [Related]  

  • 25. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
    Duboscq C; Genoud V; Parborell MF; Kordich LC
    Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture.
    Rijken DC; Binnema DJ; Los P
    Thromb Res; 1986 Jun; 42(6):761-8. PubMed ID: 2425448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Index of fibrinolysis with new fibrin plate (author's transl)].
    Hishikawa Y; Sugie I
    Nihon Seirigaku Zasshi; 1977; 39(1):1-11. PubMed ID: 140239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
    Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the murine plasma fibrinolytic system.
    Lijnen HR; van Hoef B; Beelen V; Collen D
    Eur J Biochem; 1994 Sep; 224(3):863-71. PubMed ID: 7523120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
    Ferres H
    Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of tranexamic acid on fibrinolysis, fibrinogenolysis and amidolysis.
    Takada A; Makino Y; Takada Y
    Thromb Res; 1986 Apr; 42(1):39-47. PubMed ID: 3705023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
    Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
    J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
    Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi.
    Nielsen VG
    J Thromb Thrombolysis; 2016 Jul; 42(1):33-7. PubMed ID: 26407681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma fibronectin enhances fibrinolytic system in vitro.
    Gilboa N; Kaplan JE
    Thromb Haemost; 1985 Oct; 54(3):639-44. PubMed ID: 2935966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.